Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss
Key takeaways
- Johnson & Johnson (NYSE: JNJ) is set to report Q3 FY2027 results on Nov.
- Q3 sales forecast: $70M (consensus $76M)
- 2026 earnings dilution: 64¢ per share
- 2027 earnings dilution: $1.36 per share
What happened
Johnson & Johnson (NYSE: JNJ) is set to report Q3 FY2027 results on Nov. 12. Bank of America Securities analyst Jason Gerberry forecasts sales to match consensus but earnings to fall short of expectations. He notes that earnings dilution from in‑process research and development (IPR&D) will rise to $1.36 per share in 2027, likely pushing earnings below consensus. The company is also launching Icotyde (oral IL‑23) for psoriasis and has completed the acquisition of Firefly Bio while partnering…
Why it matters
The guidance suggests JNJ’s revenue growth will stay near 6% YoY, but the higher IPR&D dilution could erode profitability, affecting investor sentiment and potentially the stock price. The launch of Icotyde and new collaborations signal continued investment in dermatology and oncology, key growth areas for the…
Short-term and longer-term
Short-term. Short‑term traders should watch the Q3 earnings release for any earnings miss that could trigger a sell‑off.
Longer-term. Longer‑term investors should note JNJ’s continued investment in dermatology and oncology, with Icotyde poised to capture a significant psoriasis market share.